A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and of adding bevacizumab to the
established regimen of vincristine, oral irinotecan, and temozolomide (VOIT) and see what
effects it has in pediatric patients with relapsed or refractory solid tumors.